Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients
Background Anemia is common among patients with chronic kidney disease (CKD). The introduction of erythropoietin treatment has changed anemia management, but the therapeutic hemoglobin (Hb) target is still under debate, and clinical evidence for its effect on cardiac functions and QOL is sparse. Met...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental nephrology 2010-02, Vol.14 (1), p.28-35 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 35 |
|---|---|
| container_issue | 1 |
| container_start_page | 28 |
| container_title | Clinical and experimental nephrology |
| container_volume | 14 |
| creator | Hirakata, Hideki Tsubakihara, Yoshiharu Gejyo, Fumitake Nishi, Shinichi Iino, Yasuhiko Watanabe, Yuzou Suzuki, Masashi Saito, Akira Akiba, Takashi Inaguma, Daijo Fukuhara, Shunichi Morita, Satoshi Hiroe, Michiaki Hada, Yoshiyuki Suzuki, Makoto Akaishi, Makoto Aonuma, Kazutaka Akizawa, Tadao |
| description | Background
Anemia is common among patients with chronic kidney disease (CKD). The introduction of erythropoietin treatment has changed anemia management, but the therapeutic hemoglobin (Hb) target is still under debate, and clinical evidence for its effect on cardiac functions and QOL is sparse.
Methods
A 16-week dose–response study and a 32-week follow-Up study were combined. After correcting anemia of less than 10 g/dl in pre-dialysis Japanese CKD patients, a higher Hb target (12–13 g/dl) by darbepoetin alfa (DPO) was compared with the conventional Hb target by epoetin alfa (EPO). Outcomes were anemia correction, management of the left ventricular mass index (LVMI) and QOL scores.
Results
No significant difference was seen in Hb at baseline and week 16, but a significant difference was recorded at week 34 (12.34 ± 0.93 g/dl for DPO and 10.43 ± 0.90 g/dl for EPO). In both groups, LVMI decreased similarly until week 16, but the decrease of EPO was retarded, and a significant difference between LVMI was seen only in DPO at week 34 (100.7 ± 16.6 g/m
2
for DPO and 110.9 ± 25.2 g/m
2
for EPO). Relationships between Hb and LVMI change at week 34 were examined by stratifying Hb into four groups (Hb |
| doi_str_mv | 10.1007/s10157-009-0212-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_218133351</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1975934141</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-2012c51ac319958fba21650dcd27d0b062fb7ab359fab0dcb6c505c6e19fded53</originalsourceid><addsrcrecordid>eNp1kc2OFCEUhYnROOPoA7gxxD3KhaJolmbib8a40TWh4FYXYxVVA1Ud-2l8Vel0J7NyQSCH756Tm0PIa-DvgHP9vgAHpRnnhnEBgjVPyDU0UjOtjXla37IRDLSCK_KilHvO-c4o85xcgdGt1I28Jn-_u5jWemLa0yHuBzrgNO_HuYuJjnjAsdA4LXk-YKDrgFXrV3rAtObot9FlOrlSkRTwD3Up0IfNjXE90rmnY-yRFj9nPAF0ychCdOOxxEK_ucUlLEj9kOcUPf0dQ8IjDbGgq_Li1lhDykvyrHdjwVeX-4b8-vTx5-0Xdvfj89fbD3fMq6ZZmeAgvALnJRijdn3nBLSKBx-EDrzjreg77TqpTO-6KnetV1z5FsH0AYOSN-Tt2beu-rBhWe39vOVUI62AHUgpFVQIzpDPcykZe7vkOLl8tMDtqRF7bsTWRuypEdvUmTcX462bMDxOXCqogDgDpX6lPebH5P-7_gNoWJp5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218133351</pqid></control><display><type>article</type><title>Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Hirakata, Hideki ; Tsubakihara, Yoshiharu ; Gejyo, Fumitake ; Nishi, Shinichi ; Iino, Yasuhiko ; Watanabe, Yuzou ; Suzuki, Masashi ; Saito, Akira ; Akiba, Takashi ; Inaguma, Daijo ; Fukuhara, Shunichi ; Morita, Satoshi ; Hiroe, Michiaki ; Hada, Yoshiyuki ; Suzuki, Makoto ; Akaishi, Makoto ; Aonuma, Kazutaka ; Akizawa, Tadao</creator><creatorcontrib>Hirakata, Hideki ; Tsubakihara, Yoshiharu ; Gejyo, Fumitake ; Nishi, Shinichi ; Iino, Yasuhiko ; Watanabe, Yuzou ; Suzuki, Masashi ; Saito, Akira ; Akiba, Takashi ; Inaguma, Daijo ; Fukuhara, Shunichi ; Morita, Satoshi ; Hiroe, Michiaki ; Hada, Yoshiyuki ; Suzuki, Makoto ; Akaishi, Makoto ; Aonuma, Kazutaka ; Akizawa, Tadao</creatorcontrib><description>Background
Anemia is common among patients with chronic kidney disease (CKD). The introduction of erythropoietin treatment has changed anemia management, but the therapeutic hemoglobin (Hb) target is still under debate, and clinical evidence for its effect on cardiac functions and QOL is sparse.
Methods
A 16-week dose–response study and a 32-week follow-Up study were combined. After correcting anemia of less than 10 g/dl in pre-dialysis Japanese CKD patients, a higher Hb target (12–13 g/dl) by darbepoetin alfa (DPO) was compared with the conventional Hb target by epoetin alfa (EPO). Outcomes were anemia correction, management of the left ventricular mass index (LVMI) and QOL scores.
Results
No significant difference was seen in Hb at baseline and week 16, but a significant difference was recorded at week 34 (12.34 ± 0.93 g/dl for DPO and 10.43 ± 0.90 g/dl for EPO). In both groups, LVMI decreased similarly until week 16, but the decrease of EPO was retarded, and a significant difference between LVMI was seen only in DPO at week 34 (100.7 ± 16.6 g/m
2
for DPO and 110.9 ± 25.2 g/m
2
for EPO). Relationships between Hb and LVMI change at week 34 were examined by stratifying Hb into four groups (Hb <10 g/dl, 10 g/dl ≤ Hb <11 g/dl, 11 g/dl ≤ Hb <12 g/dl and 12 g/dl ≤ Hb), and a decrease of LVMI was prominent in the 12 g/dl ≤ Hb group. Correction of anemia to 11 g/dl or more led to improved QOL scores. No safety difference was observed among the treatments.
Conclusions
Targeting a higher Hb around 12 g/dl was more beneficial than targeting conventional Hb in terms of reduction of LVMI and QOL. Further studies to determine the appropriate Hb target are necessary.</description><identifier>ISSN: 1342-1751</identifier><identifier>EISSN: 1437-7799</identifier><identifier>DOI: 10.1007/s10157-009-0212-4</identifier><identifier>PMID: 19763743</identifier><identifier>CODEN: CENPFV</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Adult ; Aged ; Asian Continental Ancestry Group ; Darbepoetin alfa ; Dose-Response Relationship, Drug ; Drug-Related Side Effects and Adverse Reactions ; Epoetin Alfa ; Erythropoietin - adverse effects ; Erythropoietin - analogs & derivatives ; Erythropoietin - therapeutic use ; Female ; Follow-Up Studies ; Heart Ventricles - anatomy & histology ; Heart Ventricles - drug effects ; Hemoglobins - drug effects ; Hemoglobins - metabolism ; Humans ; Hypertrophy, Left Ventricular - drug therapy ; Japan ; Kidney Failure, Chronic - drug therapy ; Kidney Failure, Chronic - physiopathology ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Nephrology ; Original Article ; Quality of Life ; Recombinant Proteins ; Urology</subject><ispartof>Clinical and experimental nephrology, 2010-02, Vol.14 (1), p.28-35</ispartof><rights>Japanese Society of Nephrology 2009</rights><rights>Japanese Society of Nephrology 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-2012c51ac319958fba21650dcd27d0b062fb7ab359fab0dcb6c505c6e19fded53</citedby><cites>FETCH-LOGICAL-c544t-2012c51ac319958fba21650dcd27d0b062fb7ab359fab0dcb6c505c6e19fded53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10157-009-0212-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10157-009-0212-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19763743$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hirakata, Hideki</creatorcontrib><creatorcontrib>Tsubakihara, Yoshiharu</creatorcontrib><creatorcontrib>Gejyo, Fumitake</creatorcontrib><creatorcontrib>Nishi, Shinichi</creatorcontrib><creatorcontrib>Iino, Yasuhiko</creatorcontrib><creatorcontrib>Watanabe, Yuzou</creatorcontrib><creatorcontrib>Suzuki, Masashi</creatorcontrib><creatorcontrib>Saito, Akira</creatorcontrib><creatorcontrib>Akiba, Takashi</creatorcontrib><creatorcontrib>Inaguma, Daijo</creatorcontrib><creatorcontrib>Fukuhara, Shunichi</creatorcontrib><creatorcontrib>Morita, Satoshi</creatorcontrib><creatorcontrib>Hiroe, Michiaki</creatorcontrib><creatorcontrib>Hada, Yoshiyuki</creatorcontrib><creatorcontrib>Suzuki, Makoto</creatorcontrib><creatorcontrib>Akaishi, Makoto</creatorcontrib><creatorcontrib>Aonuma, Kazutaka</creatorcontrib><creatorcontrib>Akizawa, Tadao</creatorcontrib><title>Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients</title><title>Clinical and experimental nephrology</title><addtitle>Clin Exp Nephrol</addtitle><addtitle>Clin Exp Nephrol</addtitle><description>Background
Anemia is common among patients with chronic kidney disease (CKD). The introduction of erythropoietin treatment has changed anemia management, but the therapeutic hemoglobin (Hb) target is still under debate, and clinical evidence for its effect on cardiac functions and QOL is sparse.
Methods
A 16-week dose–response study and a 32-week follow-Up study were combined. After correcting anemia of less than 10 g/dl in pre-dialysis Japanese CKD patients, a higher Hb target (12–13 g/dl) by darbepoetin alfa (DPO) was compared with the conventional Hb target by epoetin alfa (EPO). Outcomes were anemia correction, management of the left ventricular mass index (LVMI) and QOL scores.
Results
No significant difference was seen in Hb at baseline and week 16, but a significant difference was recorded at week 34 (12.34 ± 0.93 g/dl for DPO and 10.43 ± 0.90 g/dl for EPO). In both groups, LVMI decreased similarly until week 16, but the decrease of EPO was retarded, and a significant difference between LVMI was seen only in DPO at week 34 (100.7 ± 16.6 g/m
2
for DPO and 110.9 ± 25.2 g/m
2
for EPO). Relationships between Hb and LVMI change at week 34 were examined by stratifying Hb into four groups (Hb <10 g/dl, 10 g/dl ≤ Hb <11 g/dl, 11 g/dl ≤ Hb <12 g/dl and 12 g/dl ≤ Hb), and a decrease of LVMI was prominent in the 12 g/dl ≤ Hb group. Correction of anemia to 11 g/dl or more led to improved QOL scores. No safety difference was observed among the treatments.
Conclusions
Targeting a higher Hb around 12 g/dl was more beneficial than targeting conventional Hb in terms of reduction of LVMI and QOL. Further studies to determine the appropriate Hb target are necessary.</description><subject>Adult</subject><subject>Aged</subject><subject>Asian Continental Ancestry Group</subject><subject>Darbepoetin alfa</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Epoetin Alfa</subject><subject>Erythropoietin - adverse effects</subject><subject>Erythropoietin - analogs & derivatives</subject><subject>Erythropoietin - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Heart Ventricles - anatomy & histology</subject><subject>Heart Ventricles - drug effects</subject><subject>Hemoglobins - drug effects</subject><subject>Hemoglobins - metabolism</subject><subject>Humans</subject><subject>Hypertrophy, Left Ventricular - drug therapy</subject><subject>Japan</subject><subject>Kidney Failure, Chronic - drug therapy</subject><subject>Kidney Failure, Chronic - physiopathology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Original Article</subject><subject>Quality of Life</subject><subject>Recombinant Proteins</subject><subject>Urology</subject><issn>1342-1751</issn><issn>1437-7799</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kc2OFCEUhYnROOPoA7gxxD3KhaJolmbib8a40TWh4FYXYxVVA1Ud-2l8Vel0J7NyQSCH756Tm0PIa-DvgHP9vgAHpRnnhnEBgjVPyDU0UjOtjXla37IRDLSCK_KilHvO-c4o85xcgdGt1I28Jn-_u5jWemLa0yHuBzrgNO_HuYuJjnjAsdA4LXk-YKDrgFXrV3rAtObot9FlOrlSkRTwD3Up0IfNjXE90rmnY-yRFj9nPAF0ychCdOOxxEK_ucUlLEj9kOcUPf0dQ8IjDbGgq_Li1lhDykvyrHdjwVeX-4b8-vTx5-0Xdvfj89fbD3fMq6ZZmeAgvALnJRijdn3nBLSKBx-EDrzjreg77TqpTO-6KnetV1z5FsH0AYOSN-Tt2beu-rBhWe39vOVUI62AHUgpFVQIzpDPcykZe7vkOLl8tMDtqRF7bsTWRuypEdvUmTcX462bMDxOXCqogDgDpX6lPebH5P-7_gNoWJp5</recordid><startdate>20100201</startdate><enddate>20100201</enddate><creator>Hirakata, Hideki</creator><creator>Tsubakihara, Yoshiharu</creator><creator>Gejyo, Fumitake</creator><creator>Nishi, Shinichi</creator><creator>Iino, Yasuhiko</creator><creator>Watanabe, Yuzou</creator><creator>Suzuki, Masashi</creator><creator>Saito, Akira</creator><creator>Akiba, Takashi</creator><creator>Inaguma, Daijo</creator><creator>Fukuhara, Shunichi</creator><creator>Morita, Satoshi</creator><creator>Hiroe, Michiaki</creator><creator>Hada, Yoshiyuki</creator><creator>Suzuki, Makoto</creator><creator>Akaishi, Makoto</creator><creator>Aonuma, Kazutaka</creator><creator>Akizawa, Tadao</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20100201</creationdate><title>Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients</title><author>Hirakata, Hideki ; Tsubakihara, Yoshiharu ; Gejyo, Fumitake ; Nishi, Shinichi ; Iino, Yasuhiko ; Watanabe, Yuzou ; Suzuki, Masashi ; Saito, Akira ; Akiba, Takashi ; Inaguma, Daijo ; Fukuhara, Shunichi ; Morita, Satoshi ; Hiroe, Michiaki ; Hada, Yoshiyuki ; Suzuki, Makoto ; Akaishi, Makoto ; Aonuma, Kazutaka ; Akizawa, Tadao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-2012c51ac319958fba21650dcd27d0b062fb7ab359fab0dcb6c505c6e19fded53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Asian Continental Ancestry Group</topic><topic>Darbepoetin alfa</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Epoetin Alfa</topic><topic>Erythropoietin - adverse effects</topic><topic>Erythropoietin - analogs & derivatives</topic><topic>Erythropoietin - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Heart Ventricles - anatomy & histology</topic><topic>Heart Ventricles - drug effects</topic><topic>Hemoglobins - drug effects</topic><topic>Hemoglobins - metabolism</topic><topic>Humans</topic><topic>Hypertrophy, Left Ventricular - drug therapy</topic><topic>Japan</topic><topic>Kidney Failure, Chronic - drug therapy</topic><topic>Kidney Failure, Chronic - physiopathology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Original Article</topic><topic>Quality of Life</topic><topic>Recombinant Proteins</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hirakata, Hideki</creatorcontrib><creatorcontrib>Tsubakihara, Yoshiharu</creatorcontrib><creatorcontrib>Gejyo, Fumitake</creatorcontrib><creatorcontrib>Nishi, Shinichi</creatorcontrib><creatorcontrib>Iino, Yasuhiko</creatorcontrib><creatorcontrib>Watanabe, Yuzou</creatorcontrib><creatorcontrib>Suzuki, Masashi</creatorcontrib><creatorcontrib>Saito, Akira</creatorcontrib><creatorcontrib>Akiba, Takashi</creatorcontrib><creatorcontrib>Inaguma, Daijo</creatorcontrib><creatorcontrib>Fukuhara, Shunichi</creatorcontrib><creatorcontrib>Morita, Satoshi</creatorcontrib><creatorcontrib>Hiroe, Michiaki</creatorcontrib><creatorcontrib>Hada, Yoshiyuki</creatorcontrib><creatorcontrib>Suzuki, Makoto</creatorcontrib><creatorcontrib>Akaishi, Makoto</creatorcontrib><creatorcontrib>Aonuma, Kazutaka</creatorcontrib><creatorcontrib>Akizawa, Tadao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Clinical and experimental nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hirakata, Hideki</au><au>Tsubakihara, Yoshiharu</au><au>Gejyo, Fumitake</au><au>Nishi, Shinichi</au><au>Iino, Yasuhiko</au><au>Watanabe, Yuzou</au><au>Suzuki, Masashi</au><au>Saito, Akira</au><au>Akiba, Takashi</au><au>Inaguma, Daijo</au><au>Fukuhara, Shunichi</au><au>Morita, Satoshi</au><au>Hiroe, Michiaki</au><au>Hada, Yoshiyuki</au><au>Suzuki, Makoto</au><au>Akaishi, Makoto</au><au>Aonuma, Kazutaka</au><au>Akizawa, Tadao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients</atitle><jtitle>Clinical and experimental nephrology</jtitle><stitle>Clin Exp Nephrol</stitle><addtitle>Clin Exp Nephrol</addtitle><date>2010-02-01</date><risdate>2010</risdate><volume>14</volume><issue>1</issue><spage>28</spage><epage>35</epage><pages>28-35</pages><issn>1342-1751</issn><eissn>1437-7799</eissn><coden>CENPFV</coden><abstract>Background
Anemia is common among patients with chronic kidney disease (CKD). The introduction of erythropoietin treatment has changed anemia management, but the therapeutic hemoglobin (Hb) target is still under debate, and clinical evidence for its effect on cardiac functions and QOL is sparse.
Methods
A 16-week dose–response study and a 32-week follow-Up study were combined. After correcting anemia of less than 10 g/dl in pre-dialysis Japanese CKD patients, a higher Hb target (12–13 g/dl) by darbepoetin alfa (DPO) was compared with the conventional Hb target by epoetin alfa (EPO). Outcomes were anemia correction, management of the left ventricular mass index (LVMI) and QOL scores.
Results
No significant difference was seen in Hb at baseline and week 16, but a significant difference was recorded at week 34 (12.34 ± 0.93 g/dl for DPO and 10.43 ± 0.90 g/dl for EPO). In both groups, LVMI decreased similarly until week 16, but the decrease of EPO was retarded, and a significant difference between LVMI was seen only in DPO at week 34 (100.7 ± 16.6 g/m
2
for DPO and 110.9 ± 25.2 g/m
2
for EPO). Relationships between Hb and LVMI change at week 34 were examined by stratifying Hb into four groups (Hb <10 g/dl, 10 g/dl ≤ Hb <11 g/dl, 11 g/dl ≤ Hb <12 g/dl and 12 g/dl ≤ Hb), and a decrease of LVMI was prominent in the 12 g/dl ≤ Hb group. Correction of anemia to 11 g/dl or more led to improved QOL scores. No safety difference was observed among the treatments.
Conclusions
Targeting a higher Hb around 12 g/dl was more beneficial than targeting conventional Hb in terms of reduction of LVMI and QOL. Further studies to determine the appropriate Hb target are necessary.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>19763743</pmid><doi>10.1007/s10157-009-0212-4</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1342-1751 |
| ispartof | Clinical and experimental nephrology, 2010-02, Vol.14 (1), p.28-35 |
| issn | 1342-1751 1437-7799 |
| language | eng |
| recordid | cdi_proquest_journals_218133351 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Aged Asian Continental Ancestry Group Darbepoetin alfa Dose-Response Relationship, Drug Drug-Related Side Effects and Adverse Reactions Epoetin Alfa Erythropoietin - adverse effects Erythropoietin - analogs & derivatives Erythropoietin - therapeutic use Female Follow-Up Studies Heart Ventricles - anatomy & histology Heart Ventricles - drug effects Hemoglobins - drug effects Hemoglobins - metabolism Humans Hypertrophy, Left Ventricular - drug therapy Japan Kidney Failure, Chronic - drug therapy Kidney Failure, Chronic - physiopathology Male Medicine Medicine & Public Health Middle Aged Nephrology Original Article Quality of Life Recombinant Proteins Urology |
| title | Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T01%3A38%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Maintaining%20high%20hemoglobin%20levels%20improved%20the%20left%20ventricular%20mass%20index%20and%20quality%20of%20life%20scores%20in%20pre-dialysis%20Japanese%20chronic%20kidney%20disease%20patients&rft.jtitle=Clinical%20and%20experimental%20nephrology&rft.au=Hirakata,%20Hideki&rft.date=2010-02-01&rft.volume=14&rft.issue=1&rft.spage=28&rft.epage=35&rft.pages=28-35&rft.issn=1342-1751&rft.eissn=1437-7799&rft.coden=CENPFV&rft_id=info:doi/10.1007/s10157-009-0212-4&rft_dat=%3Cproquest_cross%3E1975934141%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218133351&rft_id=info:pmid/19763743&rfr_iscdi=true |